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Emerging Roles for Immunomodulatory
Functions of Free ISG15
Jessica A. Campbell and Deborah J. Lenschow
Type I interferons (IFNs) exert their effects through the induction of hundreds of IFN-stimulated genes (ISGs),
many of which function by inhibiting viral replication and modulating immune responses. ISG15, a di-ubiquitin-
like protein, is one of the most abundantly induced ISGs and is critical for control of certain viral and bacterial
infections. Like ubiquitin, ISG15 is covalently conjugated to target proteins. In addition, free unconjugated ISG15
is present both intra- and extracellularly. Although much remains to be learned about conjugated ISG15, even
less is known about the 2 free forms of ISG15. This article focuses on the role that ISG15 plays during the host
response to pathogen challenge, in particular on the recent observations describing the immunomodulatory
properties of free ISG15 and its potential implication in disease pathogenesis.
Introduction
Infected cells carry out signaling cascades that serve toeliminate the invading microbes and simultaneously alert
neighboring cells to the threat of potential infection. This
response is initiated by detection of pathogen-associated
molecular patterns by host pattern-recognition receptors
(PRRs), including Toll-like receptors (TLRs), RIG-I-like re-
ceptors (RLRs), and nucleic acid sensors, such as DAI, IFI16,
DHX9, and DHX36 (Kim and others 2010; Unterholzner and
others 2010; Tang and others 2012). Engagement of PRRs
triggers signaling cascades that lead to the induction of
several genes that restrict pathogen replication and modulate
the ensuing immune response. Central among this response
is the type I interferon (IFN) system and the hundreds of
effector proteins it induces. In humans and mice, the type I
IFN family is composed of 16 related members: 12 IFN-a
subtypes, IFN-b, IFN-e, IFN-k, and IFN-o, all of which bind
to the type I IFN receptor (IFNAR) (Gonzalez-Navajas and
others 2012). Binding of type I IFN to IFNAR results in ac-
tivation of the receptor-associated tyrosine kinases Jak1 and
Tyk2, which leads to STAT1- and STAT2-dependent tran-
scription of hundreds of IFN-stimulated genes (ISGs) (Gon-
zalez-Navajas and others 2012). ISGs encode proteins that
utilize diverse mechanisms to limit the spread of infection.
These mechanisms include restriction of various stages of
microbial replication, as well as immunomodulatory func-
tions. In recent years, there has been an explosion of research
focused on understanding the function of individual ISGs
and how these genes contribute to the host antiviral re-
sponse. Included among these ISGs is the ubiquitin-like
protein, ISG15.
ISG15: A Ubiquitin-Like ISG
ISG15 is one of the most robustly induced transcripts after
type I IFN stimulation (Der and others 1998). It is also up-
regulated by TLR stimulation, viral infection, and TNF-a
stimulation (Haas and others 1987; Malakhova and others
2002; Chairatvit and others 2012). ISG15 was identified in
IFN-treated lysates as a 15 kDa protein with both sequence
homology and immuno-crossreactivity to ubiquitin (Farrell
and others 1979; Blomstrom and others 1986; Haas and
others 1987). The crystal structure of ISG15 verified its sim-
ilarity to ubiquitin by revealing that it is composed of 2
ubiquitin-like (Ubl) domains connected by a short linker
(Narasimhan and others 2005). Each Ubl domain assumes a
b-grasp fold that can be superimposed onto that of the ubi-
quitin structure.
ISG15 is synthesized as a 17 kDa precursor that is pro-
teolytically processed into the mature 15 kDa form (Knight
and others 1988; Potter and others 1999). Like ubiquitin,
mature ISG15 contains a C-terminal LRLRGG motif that is
necessary for mediating its covalent formation of isopeptide
bonds to lysine residues on target proteins (Loeb and Haas
1992; Lenschow and others 2005). ISG15 conjugation, or IS-
Gylation, occurs through an enzymatic cascade that is similar
to, yet distinct from that of ubiquitin conjugation (Fig. 1). The
activating E1 enzyme, UbE1L, forms an ATP-dependent
thioester bond with ISG15 (Yuan and Krug 2001). After ac-
tivation, ISG15 is transferred to the active-site cysteine of the
conjugating E2 enzyme, Ubc8 (Kim and others 2004; Zhao
and others 2004). The E3 ligases HERC5 (human), HERC6
(mouse), HHARI, and Efp transfer ISG15 to lysine residues
on specific substrates (Dastur and others 2006; Nakasato and
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others 2006; Takeuchi and others 2006a; Wong and others
2006; Zou and others 2007; Versteeg and others 2010; Ketscher
and others 2012; Oudshoorn and others 2012). Unlike the
ubiquitin conjugation pathway, in which hundreds of E3s
ubiquitinate individual substrates, HERC5 in humans and
HERC6 in mice appear to function as the dominant E3s for the
ISG15 system because specific knockdown of their expression
with siRNA abrogates nearly all ISG15 conjugates induced by
IFN (Dastur and others 2006; Wong and others 2006; Ketscher
and others 2012; Oudshoorn and others 2012). HERC5 is as-
sociated with polyribosomes and appears to cotranslationally
modify proteins with ISG15 (Durfee and others 2010). Colo-
calization with the translational machinery may explain why
such a broad range of target proteins are conjugated by a
single E3 ligase. In contrast to ubiquitin, there currently is no
evidence that the ISG15 E3s can add ISG15 ‘‘chains’’ onto
target proteins. Rather, a single ISG15 molecule appears to be
conjugated to a lysine residue, although multiple lysines may
be modified within the same protein. Finally, conjugation to
ISG15 is not a permanent post-translational modification.
Rather, it is reversible due to specific removal of ISG15 from
conjugated proteins by the isopeptidase Ubp43 (Malakhova
and others 2002; Kim and Zhang 2005). A screen for addi-
tional deubiquitinating enzymes that could target ISG15
conjugates identified USP2, USP5, USP13, and USP14 as po-
tential candidates, although their significance remains to be
determined in vivo (Catic and others 2007). Interestingly, like
ISG15 itself, all members of the ISG15 conjugation cascade are
upregulated by type I IFNs. In addition to ISG15 conjugates,
free unconjugated ISG15 can be detected within IFN-treated
cells and can be released from cells (Fig. 1) (Knight and Cor-
dova 1991; Recht and others 1991; D’Cunha and others 1996b).
Recent efforts in the field have focused on understanding the
biological function of ISG15.
Antiviral Activity of ISG15
Despite being identified in 1979, for many years the
functional significance of ISG15 was unclear. Since ISG15
and its conjugation cascade are strongly induced by type I
IFN and IFNs play such a critical role during viral infection,
early studies focused on its potential role during viral in-
fection. Multiple approaches, including gene knockdown,
overexpression, and genetic deletion of various components
of the ISG15 cascade, have been taken to determine whether
ISG15 participates in the host response in a variety of viral
models. We will briefly summarize these results here, but
refer the reader to past reviews for a more comprehensive
analysis of the various antiviral effects of ISG15 (Harty and
others 2009; Lenschow 2010; Skaug and Chen 2010).
Several studies have shown that ISG15 regulates viral
growth in cell culture. Influenza virus, vaccinia virus, ve-
sicular stomatitis virus (VSV), Sendai virus, Japanese en-
cephalitis virus, Newcastle disease virus, avian sarcoma
leucosis virus, human papilloma virus (HPV), HIV-1, Ebola
virus-like particles (VLPs), megalocytivirus, dengue virus,
and West Nile virus (WNV) are all modestly inhibited by
ISG15 in vitro (Lenschow and others 2005; Kim and others
2006; Okumura and others 2006; Lenschow and others
2007; Guerra and others 2008; Malakhova and Zhang 2008;
FIG. 1. Schematic of the 3 forms of ISG15. The IFN-induced E1/E2/E3 enzymatic cascade catalyzes ISGylation of substrate
proteins. The activating E1 enzyme UbE1L forms a thioester bond with free ISG15 in an ATP-dependent manner (1). ISG15 is
then transferred to the E2 conjugating enzyme Ubc8 (2). Interaction with the E3 ligase HERC5 (3) then catalyzes the
conjugation of ISG15 to lysine residues of target substrate proteins (4). The deconjugating enzyme Ubp43 reverses conju-
gation by removing ISG15 from target proteins (5). Free intracellular ISG15 may bind noncovalently to unknown intracellular
proteins (6) and impact downstream signaling. Secretion of free intracellular ISG15 (7) results in extracellular ISG15 that may
bind to its unknown receptor(s) (8) to initiate unknown signaling pathways. IFN, interferon; ISG, IFN-stimulated gene.
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Okumura and others 2008; Giannakopoulos and others 2009;
Hsiang and others 2009; Lai and others 2009; Broering and
others 2010; Durfee and others 2010; Hsiao and others 2010;
Pincetic and others 2010; Shi and others 2010; Dai and others
2011; Tang and others 2012; Wang and others 2012). It is,
however, important to note that in many cases these antiviral
phenotypes have not been confirmed in an in vivo setting. In
addition, there are examples where the in vitro phenotypes
are not necessarily reflected in vivo. For example, neither
ISG15 -/- nor UbE1L -/ - mice display a phenotypic differ-
ence compared to wildtype animals during VSV infection,
despite the observation in vitro that ISG15 overexpression
lowers VSV titers (Osiak and others 2005; Kim and others
2006; Okumura and others 2008). We have also not detected
a phenotype in ISG15 -/- mice after WNV infection (Len-
schow and others, unpublished observations). The reasons
for this lack of correlation are unclear but could reflect
compensation by other ISGs in vivo, which are not evident
in vitro, when only a single cell type is being evaluated.
Clear evidence that ISG15 contributes significantly to the
host’s antiviral response was shown with the analysis of
ISG15 -/- mice. While phenotypes have not been seen in
every viral model evaluated, including both VSV and lym-
phocytic choriomeningitis virus, increased lethality was ob-
served in ISG15 deficient mice after infection with Sindbis,
influenza A and B, Chikungunya, HSV-1, and vaccinia virus
(Osiak and others 2005; Lenschow and others 2007; Guerra
and others 2008; Werneke and others 2011). Efforts to de-
termine the mechanism by which ISG15 is functioning in
these models are ongoing. To date, there are 2 mechanisms of
action that have been defined for ISG15. The first are the
conjugation dependent actions of ISG15 that inhibit viral
replication. The second are the biological properties of ISG15
that appear to be mediated by free ISG15. We will briefly
discuss the conjugation-dependent antiviral properties of
ISG15, but refer the readers to several outstanding reviews
that have been written on this topic (Knobeloch 2010; Zhang
and Zhang 2011). We will then focus the remainder of this
review on the more recent observations that have described
the immunomodulatory properties of free ISG15 and discuss
its implications on disease pathogenesis.
Conjugation-Dependent Actions of ISG15
The utilization of UbE1L -/ - mice, which lack ISG15
conjugates due to the absence of the E1 but still express free
ISG15, was vital in distinguishing whether ISGylation con-
tributed to the ISG15-dependent protection during viral in-
fection. UbE1L -/ - mice displayed a similar increase in
lethality as seen in ISG15 -/ - mice during both Sindbis and
influenza B viral infections (Giannakopoulos and others
2009; Lai and others 2009). These results indicated that ISG15
conjugates were required for the ISG15-mediated resistance
to these viruses. Further support for the importance of IS-
Gylation came from studies utilizing recombinant Sindbis
viruses. The infection of ISG15 -/ - mice with a Sindbis virus
encoding wildtype ISG15 rescued the ISG15 -/- mice from
death. In contrast, a recombinant virus expressing an ISG15
mutant in which the C-terminal LRLRGG was mutated such
that it could not undergo conjugation failed to rescue the
knockout mice, indicating that ISGylation is necessary for
the ISG15-dependent control of Sindbis virus infection
(Lenschow and others 2007).
The distinct immune evasion strategies developed by nu-
merous viruses has provided further evidence supporting
the importance of ISG15 conjugation during the antiviral
response. The influenza NS1 protein was the first im-
munoevasin to be described that antagonizes the ISG15
conjugation system (Yuan and Krug 2001). NS1B, but not
NS1A, binds noncovalently to ISG15, in a species-specific
manner, to prevent it from interacting with UbE1L, effec-
tively inhibiting conjugate formation (Yuan and Krug 2001).
Another viral protein, the vaccinia virus E3L, also inhibits
the generation of ISG15 conjugates, although the mechanism
by which this occurs is not yet understood (Guerra and
others 2008). Targeting the ISGylation system appears to be a
successful immune evasion strategy for vaccinia virus since
wildtype and ISG15 -/ - mice respond similarly to infection
with wildtype vaccinia virus, but ISG15 -/- mice displayed
increased mortality when infected with an E3L-deficient vi-
rus (Guerra and others 2008). These 2 viruses provide ex-
amples of evasion strategies that inhibit ISG15 conjugation.
In addition to influenza and vaccinia, which prevent
ISG15 conjugate formation, several viruses encode proteins
with ISG15 deconjugating activity. The L proteins from
Crimean Congo hemorrhagic fever virus (CCHFV) and
Dugbe virus and the nsP2 proteins from equine arteritis virus
and porcine respiratory and reproductive syndrome virus,
all contain ovarian tumor (OTU) domains (Frias-Staheli and
others 2007). These viral OTU-containing proteins are cys-
teine proteases with both deubiquitinating and de-ISGylat-
ing activity. The antiviral activity of ISG15 is lost in
transgenic mice expressing the CCHFV L protein during
Sindbis infection, as these mice display enhanced suscepti-
bility. Finally, the papain-like proteases of the coronaviruses
SARS and NL63 contain both deubiquitinating and de-IS-
Gylating activity (Lindner and others 2005; Clementz and
others 2010). The contribution of these ISG15 antagonists to
immune evasion in vivo is still unknown but the targeting
of ISG15 conjugates by multiple unrelated viruses suggests
that ISGylation plays an important role in host antiviral
responses.
Functions of ISGylated Proteins
To understand how ISG15 and UbE1L mediate protection
from viral infection, it is necessary to define the functional
effects of ISGylation upon modified target proteins. Nu-
merous screens and individual studies have identified sev-
eral hundred candidate ISG15 targets which span a diverse
array of biological processes and include both host and viral
proteins (Hamerman and others 2002; Kim and others 2004;
Giannakopoulos and others 2005; Takeuchi and others 2005;
Zhao and others 2005; Zou and others 2005; Takeuchi and
Yokosawa 2005; Lu and others 2006; Takeuchi and others
2006a, 2006b; Wong and others 2006; Okumura and others
2007; Zou and others 2007; Feng and others 2008; Kim and
others 2008; Shah and others 2008; Jeon and others 2009;
Durfee and others 2010; Pincetic and others 2010; Shi and
others 2010; Tang and others 2010; Zhao and others 2010;
Kuang and others 2011; Jeon and others 2012; Okumura and
others 2012). Only a limited number of these proteins have
been validated. There is currently no known universal fate
for all ISGylated proteins. Unlike K48-linked ubiquitination,
for example, ISGylation does not appear to directly target
proteins for proteasome-mediated degradation (Liu and
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others 2003). To further complicate this matter, numerous
studies have reported that only a small fraction of a given
target protein pool is ISGylated (Hamerman and others 2002;
Zhao and others 2005; Jeon and others 2009). While it is still
largely unknown what impact ISG15 modification has on a
specific protein, the field has gained some insight from the
analysis of the limited number of conjugated targets that
have been studied (Table 1). In these cases, ISG15 has been
shown to function by either disrupting the activity of a target
protein, enhancing its activity, and/or by altering its locali-
zation within the cell. There are examples of both host and
viral proteins that are modified by ISG15 that impact viral
replication. For example, ISGylation induces the autopho-
sphorylation and activation of the host protein dsRNA-
dependent protein kinase (PKR) even in the absence of viral
RNA (Okumura and others 2012). PKR activation leads to
eIF2a phosphorylation and translation suppression which
impacts upon viral replication. ISGylation of viral proteins
has also been shown to inhibit viral replication. Two differ-
ent research groups found that the NS1 protein from influ-
enza A virus is ISGylated. In 1 study the modification was
localized predominantly to the lysine at position 41 of in-
fluenza A/WSN NS1 (Zhao and others 2010). This modifi-
cation disrupts the association between NS1 and importin-a,
which is critical for nuclear translocation and replication of
influenza. Infection with a recombinant virus in which lysine
41 was mutated to arginine (K41R) resulted in reduced NS1
ISGylation. The K41R virus was less sensitive to the antiviral
effects of IFN-b pretreatment of A549 cells compared to the
wildtype virus, demonstrating that ISGylation of NS1 in-
hibits replication. Another group studying NS1 from the PR8
strain of influenza A identified lysines 126 and 127 as the
critical amino acids required for conjugation in vivo (Tang
and others 2010). Recombinant viruses encoding mutations
at either residue exhibited increased viral growth in vitro and
increased virulence in vivo. The fate of ISGylated proteins is
still an area of active research. As this body of research
continues to evolve we should gain further insight into how
ISGylation mediates antiviral activity.
Conjugation-Independent Actions of ISG15
While much of the early research in the ISG15 field has
focused on ISGylation and the identification of the members
of the ISG15 conjugation cascade, the identification of target
proteins, and analysis of the impact of ISGylation on protein
function—there has recently been increasing evidence that
free ISG15 can also play a critical role during infection.
Free ISG15 Is Present Both
Intra- and Extracellularly
In addition to the conjugated form of ISG15 that is de-
tected in cell lysates, free ISG15 exists both intra- and ex-
tracellularly. ISG15 lacks a hydrophobic leader peptide and
its release is not affected by inhibitors of the conventional
ER-Golgi secretory pathway, so it is unclear how ISG15
traffics outside the cell (D’Cunha and others 1996b). It is
possible that intracellular free ISG15 is released passively
into the extracellular space from dead or damaged cells in a
manner that is distinct from active secretion, but since the
trafficking mechanism of ISG15 is undefined we will refer to
extracellular ISG15 as secreted ISG15 in this review. Despite
its lack of a leader peptide, ISG15 can be detected in the
supernatants of type I IFN-treated leukocytes and cell lines
and in the serum from IFN-b-treated patients (Knight and
Table 1. ISGylated Target Proteins with Known Consequences of Conjugation
Protein Effect of ISGylation Modified lysine Reference
Ubc13 Suppresses thioester bond formation
to ubiquitin
92 Takeuchi and Yokosawa (2005)
UbcH6 Suppresses thioester bond formation
to ubiquitin
136 Takeuchi and others (2005)
PP2Cb Suppresses NF-kB activation 12/142 Takeuchi and others (2006)
IRF3 Inhibits ubiquitin-mediated
degradation
193/360/366 Lu and others (2006); Shi
and others (2010)
EFP Inhibits E3 ligase activity 117 Zou and others (2007)
4EHP Enhances m7GTP cap structure-binding
activity
121/130/134/222 Okumura and others (2007)
RIG-I Negatively regulates RIG-I-mediated
signaling
ND Kim and others (2008)
Cyclin D1 Suppresses cyclin D1 protein levels ND Feng and others (2008)
PML/RARa Represses PML domain ND Shah and others (2008)
Filamin B Inhibits ability to scaffold RAC1,
MEKK1, and MKK4
2467 Jeon and others (2009)
Influenza A NS1 Inhibits nuclear import; inhibits
dimerization
41;20/31/108/110/
126/217/219
Tang and others (2010);
Zhao and others (2010)
CHMP5 Inhibits CHMP5-LIP5 interaction ND Pincetic and others (2010)
CHMP2A Inhibits CHMP2A-LIP5 interaction ND Kuang and others (2011)
CHMP4B Inhibits binding to Vps4 ND Kuang and others (2011)
CHMP6 Inhibits binding to Vps4 ND Kuang and others (2011)
DNp63a Becomes susceptible to caspase-2
cleavage
139/324 Jeon and others (2012)
PKR Activates PKR in absence of viral RNA 69/159 Okumura and others (2012)
ND, not determined.
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Cordova 1991; Recht and others 1991; D’Cunha and others
1996b). The existence of a secreted form of ISG15 suggested
that it might bind to a cell surface receptor to modulate in-
tracellular signaling events during an immune response.
Although the identity of a cell surface receptor(s) for ISG15 is
currently unknown, multiple studies have indicated that
secreted ISG15 has cytokine-like activity. In contrast, much
less is known about the function of unconjugated ISG15 that
exists within the cell. However, recent studies have sug-
gested that both forms of free ISG15 may be functional.
Models of Positive Regulation by Free ISG15
The initial investigation into whether secreted ISG15 has
biological activity reported that recombinant soluble ISG15
could induce T cells, but not natural killer (NK) cells, to se-
crete IFN-g (Recht and others 1991). It was further shown
that incubation with ISG15 enhanced the LPS-induced cy-
tolytic activity of peripheral blood mononuclear cell (PBMC)
cultures. This was attributed to the ISG15-induced produc-
tion of IFN-g by T cells, which then activated monocytes. The
ability of ISG15 to induce IFN-g secretion by T cells was
confirmed in a subsequent study demonstrating that re-
combinant ISG15 could stimulate significant NK cell prolif-
eration when added to PBMC cultures (D’Cunha and others
1996a). This effect was indirect because ISG15 did not stim-
ulate proliferation of purified NK cells alone, but required
total PBMCs. The results from these 2 early articles suggested
a model in which ISG15 release from IFN-stimulated cells
induced the production of IFN-g by T cells with subsequent
monocyte and NK cell activation. For these reasons, it was
suggested that secreted ISG15 could regulate the immune
response after type I IFN production.
After these early reports, another group examined the effect
of ISG15 on dendritic cells (Padovan and others 2002). Using
microarray analysis to identify melanoma cell-derived soluble
factors that could impair DC migration, it was shown that
ISG15 upregulated E-cadherin, CD15, and CD86 expression on
monocyte-derived DCs. Soon after it was shown that ISG15
was localized to the extracellular surface of erythrocytes that
were either uninfected or undergoing an early stage infec-
tion with Plasmodium yoelii, while erythrocytes containing the
later schizont stage parasites lacked surface ISG15 staining
(Owhashi and others 2003). ISG15 derived from the uninfected
or early stage-infected erythrocytes was shown to act as a
chemoattractant for and activator of neutrophils.
Taken together, these 4 initial studies suggested that se-
creted ISG15 acts as a positive regulator of multiple cell
types. A recent study by Casanova and colleagues of patients
with Mendelian susceptibility to mycobacterial disease
(MSMD) has provided further evidence that ISG15 can
function as an immunomodulatory cytokine (Bogunovic and
others 2012). Through the use of whole-exome sequencing
and genome-wide linkage analysis they identified 3 patients,
including 2 siblings, encoding homozygous mutations in
ISG15. The mutations were different between the 2 families,
but both resulted in a loss of ISG15 protein expression. Cells
derived from these patients lacked free and conjugated
ISG15, although both could be reconstituted after transfec-
tion of wildtype ISG15, indicating that the ISGylation
machinery was intact. After stimulation with Bacillus Calmette-
Gue´rin (BCG), a vaccine strain of Mycobacterium bovis,
both PBMCs and neutrophils from control but not ISG15 -/ -
patients secreted ISG15. These data provided the first evi-
dence in humans that inherited mutations in ISG15 can lead
to the loss of protein expression.
The characterized germline mutations associated with
MSMD are located in genes whose protein products are in-
volved in IFN-g signaling (Cottle 2011). Given this, the au-
thors revisited the idea that ISG15 functions as a cytokine to
regulate IFN-g production and compared ISG15-mediated
IFN-g production in cells from control and ISG15 -/ - pa-
tients. In accordance with earlier studies, the addition of
recombinant ISG15 to the culture medium of control PBMCs
induced IFN-g production. Interestingly, coincubation of
PBMCs with ISG15 and IL-12 greatly augmented IFN-g se-
cretion compared to ISG15 alone, suggesting that a syner-
gistic relationship exists between these 2 cytokines. In this
study NK cells, not T cells, were the main IFN-g producer.
The reason for this is unknown but may be explained by the
difference in IL-12 costimulation, which was not performed
in the earlier studies. After stimulation with BCG alone or
BCG and IL-12, ISG15 -/ - PBMCs were found to secrete less
IFN-g than control PBMCs, despite normal expression of
both IL-12p40 and IL-12p70. Importantly, in the presence of a
monoclonal antibody against ISG15, IFN-g production was
greatly reduced when control PBMCs were stimulated with
BCG or BCG plus IL-12. Flow cytometric analysis revealed
CD3 + cells as the main population to lose IFN-g production
during ISG15 blockade, while CD3 - cells exhibited a less
severe reduction. Exogenous ISG15 was able to partially re-
constitute the phenotype. Recombinant ISG15 did not rescue
IFN-g production by ISG15 -/- PBMCs stimulated with BCG
alone, but it did increase IFN-g secretion when the cells were
stimulated with BCG plus IL-12. In addition, while exoge-
nous ISG15 increased the number of CD56 + IFN-g + cells in
BCG plus IL-12-stimulated ISG15 -/ - cultures, it was not
effective in restoring the CD56- IFN-g + population. While it
is clear that cells derived from ISG15 -/ - patients produce
less IFN-g upon BCG challenge, the inability of recombinant
soluble ISG15 to fully restore both the population of IFN-g +
cells and the total amount of secreted IFN-g raises the pos-
sibility that other defects may also contribute to this phe-
notype. Sequence analysis identified 2 other homozygous
coding variants located in the chromosomal regions linked to
MSMD in one ISG15 -/ - patient and 9 in another. It is pos-
sible that these mutations also contribute to susceptibility to
MSMD and perhaps to the regulation of IFN-g by ISG15.
Despite this, the defective IFN-g production from ISG15-/-
cells and the critical role of IFN-g in mycobacterial immune
responses suggest a model in which BCG stimulates secretion
of ISG15, which then synergizes with IL-12 to promote IFN-g
production from CD56+ and CD3+ cells. In this model,
the ISG15-dependent production of IFN-g is abrogated in
patients with ISG15 deficiency and is responsible for the
improper control of mycobacteria. The authors also reported
that ISG15-/- mice were more susceptible than wildtype
mice to infection with Mycobacterium tuberculosis infection,
although whether this increased susceptibility was indepen-
dent of conjugation was not assessed. This in vivo model will
be a useful tool in further dissecting the role of ISG15 in
mycobacterial pathogenesis.
Finally, a recent study has shown that secreted ISG15
exerts immunoregulatory effects not only in mammals but
also in teleost (fish) species (Wang and others 2012). When
added to the media of macrophages from the tongue sole
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Cynoglossus semilaevis, recombinant soluble ISG15 induced
respiratory burst and nitric oxide production. Soluble ISG15
also enhanced the expression of several immune genes in
C. semilaevis lymphocyte cultures, including TLR9, IL-8, and
IL-1b. Interestingly, while the effects on macrophages were
dependent on the C-terminal LRGG residues of ISG15, the
phenotypes in lymphocytes had mixed dependence on this
motif. The wildtype C-terminus was required for IL-8 induc-
tion, but TLR9 and IL-1bwere still induced by a mutant ISG15
in which the C-terminus was mutated to LAAG. This was the
first study to suggest a role for the LRGG motif of ISG15 for
something other than conjugation. This report also highlights
the significance of ISG15 in nonmammalian species and again
suggests species-specificity for various effects of ISG15.
There are several important observations that come from
these studies and should help to guide future work on the
cytokine activity of ISG15. First, several of these studies
support the ability of ISG15 to function as an immunomod-
ulatory molecule, with the strongest evidence being its abil-
ity to regulate IFN-g production. Whether ISG15 regulates
other cytokines or chemokines in these models is unclear. In
the study of C. semilaevis ISG15, both IL-8 and IL-1b were
also induced by ISG15, raising the possibility that in the
correct setting or by stimulating different cell types, ISG15
may regulate additional pathways (Wang and others 2012).
Second, these studies indicated that ISG15 can be released
from different cell types, although the mechanisms may be
distinct. Neutrophils were found to contain ISG15 in gelati-
nase and secretory granules even in an unstimulated state
(Bogunovic and others 2012). However, ISG15 was also
found to be on the surface of erythrocytes during malaria
infection and released from lymphocytes and monocyte
during type I IFN treatment (Knight and Cordova 1991;
D’Cunha and others 1996b; Owhashi and others 2003). The
mechanisms by which it gets released from these different
cell types will need to be investigated further. Finally, these
studies may provide important clues that will lead to the
identification of the ISG15 receptor. The synergy noted be-
tween ISG15 and IL-12 in the Casanova study could indicate
that the receptor is induced by IL-12 or works in concert with
another IL-12-induced protein to stimulate IFN-g production.
The study in C. semilaevis which revealed that the LRGG
motif was important for this stimulatory activity may also
provide important insight into the structure of released
ISG15, which will be critical in moving forward. Finally, in
all of these studies, different cell types were found to re-
spond to ISG15, providing insight into which cell types may
express an ISG15 receptor.
Model of Negative Regulation by Free ISG15
All of the studies evaluating the cytokine–like activity of
ISG15 were performed in vitro, and early studies using the
knockout mouse models had indicated the antiviral activities
of ISG15 were conjugation-dependent, with the ISG15 -/-
and UbE1L -/ - mice phenocopying each other. However, a
recent study using a neonatal model of Chikungunya virus
(CHIKV) provided the first in vivo evidence that free ISG15
contributes to the host response during viral infection
(Werneke and others 2011). CHIKV is an arthropod-borne
alphavirus that causes an acute febrile arthritis of the pe-
ripheral joints in affected patients. Using a murine model of
CHIKV, Werneke and others were able to demonstrate a
significant increase in lethality in mice lacking ISG15, with
100% of ISG15 -/- mice succumbing to infection within 3–4
days as compared to only 40% lethality in wildtype mice at
later times postinfection. Unlike previously described influ-
enza and Sindbis virus models, where the antiviral activity
of ISG15 was dependent on conjugation, during CHIKV
infection the action of ISG15 was independent of UbE1L-
mediated conjugation. UbE1L -/- mice displayed no in-
crease in lethality and instead phenocopied the wildtype
mice. Since these mice lack ISG15 conjugates but still contain
free ISG15, this study implied that the protection afforded by
ISG15 was not dependent on its conjugated form but rather
on free ISG15. It should be noted that there is the possibility
that UbE1L is not the only E1 enzyme for ISG15, and that an
alternative E1 could generate low levels of ISG15 conjugates
that protect these mice from CHIKV infection. However, no
other E1 enzyme has been identified for the ISG15 pathway
and ISG15 conjugates were not detected by immunoblot in
UbE1L -/ - mice or cells. It also possible that UbE1L has an
ISG15-independent function that is crucial for resistance to
CHIKV—but aside from its role as an E1 no other functions
are currently known. Therefore, it is likely that free ISG15
mediates the resistance to CHIKV-induced lethality.
Although this study indicated that free ISG15 was required
for protection during CHIKV infection, its role was not directly
antiviral. In contrast to the conjugation-dependent influenza
and Sindbis virus models that resulted in dramatically higher
viral loads in both ISG15-/- and UbE1L-/- mice, ISG15
deficiency did not lead to increased CHIKV titers in any organ
tested. Instead, mice lacking ISG15 were found to have ele-
vated levels of several proinflammatory cytokine and chemo-
kines. TNF-a, IL-1b, IL-6, CCL2, CCL3, and CCL5 levels in
ISG15-/- mice were as high or higher than those seen in
IFNAR-/- mice, which die from CHIKV infection even more
rapidly than ISG15-/- mice. Mice lacking ISG15 displayed
clinical signs of shock, including elevated liver enzymes and
blood urea nitrogen levels, and the blockade of proin-
flammatory cytokines was able to prolong survival of these
mice, suggesting that cytokine storm was contributing to the
increased lethality (Lenschow and others, unpublished obser-
vations). These data indicate that free ISG15 functions not as
an antiviral factor, but as an immunomodulatory protein that
negatively regulates the expression of proinflammatory cyto-
kines and chemokines.
While this study provided the first in vivo evidence that
free ISG15 contributed to the host response during viral
infection, it does not distinguish between the actions of
extracellular or intracellular free ISG15. The actions of ex-
tracellular ISG15 have been most clearly tied to the induction
of IFN-g secretion by cytotoxic lymphocytes. However, in
the CHIKV model, wildtype, ISG15 -/ - , and UbE1L -/-
mice produced equivalent IFN-g levels during the course of
the infection (Lenschow and others, unpublished data), im-
plying that IFN-g production is sufficient or unnecessary in
CHIKV-infected ISG15 -/- mice. Several other cytokines and
chemokines were upregulated in CHIKV-infected ISG15 -/-
mice. Therefore, it is possible that secreted ISG15 may bind
to a cell surface receptor that downregulates these cytokines.
The absence of ISG15 then would result in their elevation.
Since the receptor(s) for ISG15 has not been identified, it is
difficult to know how free ISG15 is acting in this system.
Blocking antibodies and/or a mutated ISG15 that lacks re-
ceptor binding would be essential tools in defining whether
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the protection mediated by ISG15 in the CHIKV model is
through the action of extracellular, free ISG15. However,
both of these approaches require knowledge of the receptor’s
identity.
An alternative explanation to the ISG15-dependent,
UbE1L-independent protection against CHIKV infection is
that free intracellular ISG15 is responsible for the effect by
binding noncovalently to other intracellular proteins and
modulating their functions. This noncovalent, intracellular
interaction appears to control the ability of Ebola VLPs to
egress from cells in vitro. Ebola VLP budding requires
ubiquitination of the VP40 viral matrix protein through its
interaction with Nedd4, a host E3 ubiquitin ligase. Over-
expression of ISG15, independent of the conjugation cascade,
was shown to inhibit Ebola VP40 VLP budding from 293T
cells by binding to the Nedd4 ligase and disrupting the in-
teraction between Nedd4 and the E2 enzyme UbcH6, which
is required for ubiquitin transfer (Malakhova and others
2008; Okumura and others 2008). This resulted in reduced
VP40 ubiquitination and less efficient VLP budding. Al-
though these studies have yet to be confirmed in vivo, they
suggest that free intracellular ISG15 can modulate intracel-
lular biochemical events. With respect to CHIKV infection, it
is unlikely that free intracellular ISG15 alters a binding event
that affects viral production, since titers are similar between
wildtype, ISG15 -/- , and UbE1L -/ - mice. However, it is
possible that ISG15 impacts intracellular host protein inter-
actions that regulate cytokine and chemokine production.
Further examination of intracellular, noncovalent binding
partners of ISG15 will shed further light on this matter.
Ongoing work will help define whether free ISG15 is re-
quired in its intracellular and/or extracellular form during
CHIKV-infection and in other model systems.
Defining the Mechanisms of ISG15-Dependent
Immunomodulation
It is now clear that certain conditions exist in which free
ISG15 acts as a positive regulator of cytokine production,
particularly with regard to IFN-g (Fig. 2). In contrast, other
systems implicate free ISG15 as a negative regulator of
cytokine production. How can these seemingly opposite sce-
narios be reconciled, especially when the molecular mecha-
nisms by which they are each mediated are unknown? One
explanation may be that secreted ISG15 binds to a cell surface
receptor that stimulates IFN-g production. The 3 studies using
recombinant soluble ISG15 as an inducer of IFN-g support this
hypothesis. In contrast, intracellular free ISG15 may interact
within cytoplasmic signaling networks to downmodulate
proinflammatory cytokine production. Discovery of the ex-
tracellular and intracellular proteins with which ISG15 inter-
acts will be necessary to confirm these hypotheses.
The identity of the receptor to which secreted ISG15 binds
will be fundamental to our understanding of ISG15 biology.
It is possible that more than 1 receptor exists for ISG15, es-
pecially since it has been shown to directly modulate the
functions of or bind to diverse cell types, including T cells,
NK cells, neutrophils, DCs, macrophages, and red blood
cells. The receptor may be localized on the cell surface, where
it could bind ISG15 in the extracellular space, or it may be
localized inside cytoplasmic vesicles, in which case endocy-
tosis could deliver ISG15 to its receptor. Two other Ubls,
SUMO-3 and MNSF-b, along with ubiquitin itself, are pres-
ent extracellularly (Nakamura and others 1996; Hosono and
Yokosawa 2008; Majetschak 2011). The receptors for SUMO-
3 and MNSF-b are unknown, but ubiquitin binds to the
chemokine receptor CXCR4 (Saini and others 2010). Since
ubiquitin and Ubls adopt a similar 3-dimensional structure,
it will be interesting to learn whether they also bind receptors
with structural similarity. The novel finding that IL-12 sy-
nergizes with ISG15 to induce IFN-g expression raises the
possibility that IL-12 may induce expression of the ISG15
receptor, a situation that should be examined.
The work on Ebola VLPs demonstrated that free intra-
cellular ISG15 can bind noncovalently to cytoplasmic pro-
teins to alter their functions. It is conceivable that ISG15
interacts with other unidentified intracellular proteins inde-
pendent of conjugation. Recent work in the ubiquitin field
has demonstrated that unanchored ubiquitin chains can bind
to innate signaling molecules, such as RIG-I and members of
the NF-kB signaling cascade to influence signaling through
these important pathways (Xia and others 2009; Zeng and
others 2010). This raises the possibility that other Ubls could
function in a similar manner. The body of research on non-
covalent binding partners of ISG15 is quite small compared
to the conjugation-dependent interactions, but these inter-
actions may influence important biological processes. Un-
covering these binding partners for ISG15 will be
instrumental in understanding its molecular mechanism.
Concluding Remarks
Significant progress has been made over the past several
years with respect to the identification of the ISG15
FIG. 2. Secreted ISG15 modulates the activities of multiple
mammalian cell types. ISG15 has been shown to alter the
phenotypes of various cells. T and NK cells secrete IFN-g
upon ISG15 stimulation, while dendritic cells upregulate
expression of E-cadherin, CD15, and CD86 in response to
ISG15. ISG15 enhances the chemotactic activity of neutro-
phils. Although ISG15 has been detected on the surface of
red blood cells, it is not known what the functional impact of
this is.
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conjugation machinery, the identities of proteins that un-
dergo ISGylation, and the role of ISG15 as an antiviral factor
with both conjugation-dependent and-independent modes of
action. Despite these achievements, many questions still re-
main for all 3 forms of ISG15. With respect to the conjuga-
tion-dependent aspects of ISG15, a very small proportion of
the identified ISGylated host target proteins have been ex-
amined. Additionally, with the exception of influenza and
HPV proteins, it is unknown whether other viral or bacterial
proteins are modified by ISG15. The elucidation of the
functional consequences of ISGylation of both host and mi-
crobial proteins will be important in understanding the
conjugation-dependent role of ISG15 during infection. The
recognition that several viruses encode immune evasion
proteins aimed at disrupting conjugation suggests that IS-
Gylation is an important post-translational modification
during infection. Mutant viruses that lack this evasion tactic
may be useful tools in the identification of ISGylated proteins
that are vital to viral control.
Important advances have also been made in the study of
free ISG15. Identification of the proteins that bind non-
covalently to free intracellular ISG15 is just beginning, but
will shed light on the mechanism by which ISG15 may di-
rectly participate in intracellular signaling pathways. Simi-
larly, identification of the receptor for secreted ISG15 will
clarify how ISG15 can induce diverse phenotypes on various
cell types.
Addressing these remaining questions will undoubtedly
provide interesting insights into the basic biology of ISG15.
At the same time, a better understanding of the antiviral
and immunomodulatory activities of ISG15 may aid the
development of therapeutics targeted at ISG15. For exam-
ple, since ISGylation is important to the host response to
multiple viruses, inhibition of the deconjugating enzyme
Ubp43 may be a useful strategy to augment the antiviral
activity of ISG15 conjugation. Other circumstances may
benefit from the manipulation of free ISG15. Since secreted
ISG15 induces IFN-g secretion, recombinant ISG15 may be a
valuable tool when greater IFN-g levels would be benefi-
cial, such as during insufficient responses to mycobacteria.
Conversely, neutralization of secreted ISG15 may contrib-
ute to the dampening of IFN-g-mediated immunopathol-
ogy. Finally, depending on the nature of the interactions
between free intracellular ISG15 and its noncovalent bind-
ing partners, small molecule inhibitors and/or antagonists
may allow us to modify the inflammatory cytokines that
ISG15 negatively regulates. Further examination into the
mechanisms of all 3 forms of ISG15 will help us progress
toward these exciting possibilities.
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